Human fibrin glue, composed of fibrinogen and thrombin from human plasma, plays a crucial role in surgical procedures by mimicking the body's blood clotting process. It forms stable fibrin clots upon application, sealing wounds, promoting hemostasis, and facilitating tissue adhesion. The market for fibrin glue is driven by the increasing prevalence of surgeries worldwide, especially in cardiovascular, orthopedic, and general surgery fields. Its benefits in promoting faster wound healing, reducing blood loss, and minimizing postoperative complications contribute to its adoption. Furthermore, advancements in surgical techniques and an aging population necessitating surgical interventions further boost demand. Fibrin glue's suitability for minimally invasive procedures also enhances its market growth as it offers an effective alternative to traditional sutures or staples.
Global Human Fibrin Glue Market size was valued at USD 486.58 million in 2021 and is projected to reach USD 934.68 million by 2029, with a CAGR of 9.2% during the forecast period of 2021-2029.
To know more, visit https://www.databridgemarketresearch.com/pt/reports/global-human-fibrin-glue-market
Below are the Top Human Fibrin Glue Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
CSL Limited
|
A global biopharmaceutical company, known for its expertise in plasma-derived therapies. CSL produces human fibrin glue as part of its portfolio of hemostasis and tissue sealing products.
|
|
Americas, Asia-Pacific, Europe, and Middle east and Africa
|
In June 2020, CSL acquired Vitaeris Inc., a clinical-stage biotechnology company to broaden their brand and product portfolio.
|
|
2.
|
Johnson & Johnson Services, Inc.
|
Renowned for its diverse healthcare products, Johnson & Johnson offers surgical adhesives, including human fibrin glue, under its Ethicon brand, catering to various medical needs such as wound closure and tissue sealing.
|
|
Americas, Asia-Pacific, Europe, and Middle east and Africa
|
In December 2019, Ethicon Part of The Johnson & Johnson Family of Companies announced that they have launched VISTASEAL Fibrin Sealant (Human) to help surgeons manage bleeding during surgery which contains a combination of fibrinogen and thrombin, clotting proteins found in human plasma. This development increased the company’s product pipeline.
|
|
3.
|
Baxter
|
A leading healthcare company, Baxter manufactures human fibrin glue as part of its surgical sealants and hemostats portfolio. Their products are utilized in diverse medical settings for sealing tissues and promoting hemostasis.
|
|
Americas, Asia-Pacific, Europe, and Middle east and Africa
|
In August 2021, Baxter’s subsidiary Baxter Healthcare Corporation completed the acquisition of certain assets related to PerClot Polysaccharide Hemostatic System from CryoLife, Inc. This have helped the company to expand advanced surgery portfolio.
|
|
4.
|
Hualan Biological Engineering Inc.
|
A prominent Chinese biopharmaceutical company, Hualan specializes in the research, development, and production of biologics, including human fibrin glue, contributing to the domestic and international markets.
|
|
China
|
Since its launch in China, the sales value of Fibrin Sealant (Human) has steadily increased, hitting approximately CNY 144 million in 2017. Hualan Biological Engineering Inc. has emerged as the dominant player in China's Fibrin glue (Human) market, capturing over 90% of the market share by sales value. This significant market dominance underscores Hualan Biological Engineering Inc.'s strong position and such asly reflects its effective marketing strategies, product quality, and competitive pricing in the segment.
|
|
5.
|
Shanghai RAAS
|
Known for its focus on biopharmaceuticals and medical devices, Shanghai RAAS produces human fibrin glue as part of its surgical products line, providing solutions for wound closure and tissue bonding in clinical settings.
|
|
America, Asia, Europe, and Africa
|
In February 2016, Shanghai RAAS announced that they have received approval of Plasma Collection Station issued by Health and Family Planning Commission of Guangdong Province, approving Shanghai RAAS to set up Plasma Collection Station in Luhe County and urban area in Shanwei City. This approval of the two plasma collection stations will have a positive effect on the long-term product development of the Company.
|
Conclusion
The global human fibrin glue market is witnessing substantial growth, driven by increasing surgical procedures worldwide and the product's efficacy in promoting wound healing and reducing complications. Key players such as CSL Limited, Johnson & Johnson Services, Inc., and Baxter dominate the market with their extensive product portfolios and global presence. It is used in cardiovascular surgery, where fibrin glue effectively seals vascular anastomoses, reducing the risk of bleeding and improving patient outcomes. As surgical techniques advance and the aging population grows, the demand for human fibrin glue is expected to surge further.
